Design, synthesis, and investigation of lipid-lowering and hepatoprotective effects of clofibrate-vanillin derivative based on structural optimization

Area of Science:

• Pharmacology
• Hepatology
• Medicinal Chemistry

Background:

• Clofibrate is a lipid-lowering drug with known hepatotoxicity.
• Optimizing clofibrate structure is crucial for developing safer lipid-lowering agents.

Purpose of the Study:

• To synthesize and evaluate clofibrate-vanillin (CF-Vanillin) as a novel lipid-lowering agent.
• To assess the efficacy of CF-Vanillin in reducing liver damage compared to clofibrate (CF).

Main Methods:

• Synthesis of clofibrate-vanillin.
• In vivo testing in hyperlipidemic mice.
• Molecular docking studies targeting PPAR-α.
• Biochemical assays for liver enzymes (AST, ALT) and lipid profiles (TG, TC).
• Histopathological examination of liver tissues.
• Analysis of Nrf2 and HO-1 gene expression.

Main Results:

• CF-Vanillin demonstrated superior reduction of triglycerides and total cholesterol compared to CF.
• CF-Vanillin significantly decreased liver weight, liver coefficient, AST, and ALT levels.
• Histopathology revealed reduced liver damage, including less nuclear deformation, inflammation, and necrosis.
• Molecular docking indicated favorable binding affinity of CF-Vanillin to PPAR-α.
• Upregulation of Nrf2 and HO-1 expression was observed in CF-Vanillin treated mice.

Conclusions:

• CF-Vanillin exhibits enhanced lipid-lowering effects and reduced hepatotoxicity compared to clofibrate.
• The protective effects of CF-Vanillin against liver damage are likely mediated by its antioxidant and anti-inflammatory properties.
• Activation of the Nrf2/HO-1 signaling pathway contributes to the therapeutic benefits of CF-Vanillin.